CLOV Stock Clover Health Investments (CLOV, $3.11) RSI Indicator left the oversold zone on December 13, 2024

GET DAILY SIGNALS

Get AI intraday signals

CLOV - Clover Health Investments Corp

RSI signal

View

Odds of UP Trend

Price: $3.11

Daily change: +$0.11 (+3.67%)

Daily volume: 4.4M

Capitalization: $1.6B

Industry: Managed Health Care

CLOV in downward trend: 10-day moving average moved below 50-day moving average on November 18, 2024

The 10-day moving average for CLOV crossed bearishly below the 50-day moving average on November 18, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 09, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CLOV as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLOV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CLOV entered a downward trend on December 16, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLOV's RSI Oscillator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 53 cases where CLOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CLOV just turned positive on December 20, 2024. Looking at past instances where CLOV's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .

CLOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.331) is normal, around the industry mean (3.063). CLOV's P/E Ratio (0.000) is considerably lower than the industry average of (17.509). CLOV's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.089). CLOV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.020). P/S Ratio (0.182) is also within normal values, averaging (0.684).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.